【摘要】 目的:探讨重组人干扰素注射液肌肉注射联合干扰素阴道栓剂治疗宫颈高危型HPV感染的疗效。方法:83例宫颈高危型HPV感染患者以半随机方式分为治疗组和对照组,其中治疗组46例,用重组人干扰素α1b注射液50μg,肌肉注射,每日1次,连续10天为1疗程,然后用重组人干扰素α2b阴道栓每次1粒,隔日1次,9粒为1疗程。以上药物每个月1疗程,连用3个月。对照组37例,不给予药物治疗。结果:治疗结束6个月后复查宫颈高危型HPVDNA,治疗组痊愈率46.34%(19/41),有效率80.49%(33/41);对照组痊愈率16.67%(5/30),有效率53.33%(16/30)。经χ2检验,治疗组的痊愈率、有效率均显著高于对照组(χ2=6.276,0.01<P<0.05;χ2=5.352,0.01<P<0.05)。结论:重组人干扰素肌肉注射与干扰素阴道栓剂联合使用,是治疗宫颈高危型HPV感染的有效方法之一。更多还原

【Abstract】 Objectives: To investigate the possible efficacy of combined use of recombinant human interferon α1b injection and interferon α2b vaginal suppository in the treatment of female cervical high risk human papillomavirus(HR-HPV) infection.Methods: Eighty-three patients with cervical HR-HPV infection were semi-randomly divided into two groups.For the 46 cases in the treatment group,one treatment course includes intramuscular injection of 50μg interferon α1b once daily for 10 days,combined with the administration of interferon α2b vaginal suppository every other day for 18 days.One treatment course took one month and the whole treatment lasted for three months.The control group received no treatment.Result:Cervical HR-HPV DNA were retested six months after the treatment.The curative rate and effective rate in the treatment group were 46.34%(19/41)and 80.49%(33/41) respectively,being significantly higher than those in the control group(16.67%(5/30) and 53.33%(16/30)(χ2=6.276,0.01<P<0.05;χ2=5.352,0.01<P<0.05).Conclusion: Intramuscular recombinant human interferon combined with interferon vaginal suppository is an effective method for the treatment of cervical HR-HPV infection.更多还原